View Post

Results From Combination of APR-246 with Immuno-Oncology Agents Presented at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta

In Clinical Trials by Barbara Jacoby

From: prnewswire.com Studies support synergistic role of p53 stabilization by APR-246 in combination with immuno-oncology agents Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the …

View Post

Targeting triple-negative breast cancer with new drug design

In In The News by Barbara Jacoby

By: Laura Castañón, Northeastern University From: medicalxpress.com The type of breast cancer most likely to affect young people and African Americans is also one of the most aggressive and difficult to treat. Triple-negative breast cancer, which represents about 20 percent of all breast cancer cases, is named for its lack of three common hormone receptors. Since targeted breast cancer treatments …

View Post

Cyclacel Pharma (CYCC) Presents Phase 1 Data of Sapacitabine Regimen in Patients With BRCA Mutant Breast Cancer at AACR 2019

In Clinical Trials by Barbara Jacoby

From: streetinsider.com Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) announced Phase 1 clinical data from the company’s DNA damage response program with an oral, sequential regimen of sapacitabine and seliciclib as a treatment in patients with BRCA mutant metastatic breast cancer. Data from the study was presented today at the 2019 American Association for Cancer Research (AACR) Annual Meeting and demonstrated that …

View Post

New role for a driver of metastatic cancers

In In The News by Barbara Jacoby

Source: Salk Institute for Biological Studies From: prnewswire.com Salk scientists uncover the mechanism of a gene to better target cancer therapy Metastatic ovarian, prostate and breast cancers are notoriously difficult to treat and often deadly. Now, Salk Institute researchers have revealed a new role for the CDK12 protein. The findings were published in the print version of Genes & Development …

View Post

Constellation Pharmaceuticals Presents Results from Phase 1b Portion of ProSTAR Clinical Trial of CPI-1205 at AACR Meeting

In Clinical Trials by Barbara Jacoby

Source: Constellation Pharmaceuticals , Inc. From: globenewswire.com Clinical activity of CPI-1205 was seen in subsets of advanced metastatic castration-resistant prostate cancer (mCRPC) patients Recently initiated Phase 2 portion of ProSTAR includes randomized testing of CPI-1205 in combination with enzalutamide versus enzalutamide alone, as well as CPI-1205 in combination with abiraterone Initial update from Phase 2 portion of ProSTAR expected in …

View Post

Breast cancer study by UCR medical student could help patients live longer

In In The News by Barbara Jacoby

By: Iqbal Pittalwala From: ucr.edu A student at the University of California, Riverside, presented research results at the annual meeting of the American Association for Cancer Research, or AACR, in Atlanta showing that surgery is associated with higher survival rates for patients with HER2-positive stage 4 breast cancer compared with those who did not undergo surgery. The protein HER2, or …

View Post

UC San Diego Health treats 1st cancer patient with stem-cell derived natural killer cells

In Clinical Trials by Barbara Jacoby

Source: University of California-SanDiego From: eurekalert.org After 10 years in remission, Derek Ruff’s cancer returned, this time as stage IV colon cancer. Despite aggressive rounds of chemotherapy, palliative radiotherapy and immunotherapy, his disease progressed. In February 2019, as part of a phase I clinical trial at Moores Cancer Center at UC San Diego Health, Ruff became the first patient in …

View Post

Immunotherapy combination effective for patients with rare neuroendocrine cancer

In Clinical Trials by Barbara Jacoby

Source: SWOG From: eurekalert.org A combination of two common immunotherapy drugs shrinks rare, aggressive neuroendocrine tumors, according to new research results presented at the American Association for Cancer Research Annual Meeting 2019, held March 29-April 3 in Atlanta. Results from the SWOG Cancer Research Network trial known as DART, short for Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors, show …

View Post

Major step towards individual cancer immunotherapy

In In The News by Barbara Jacoby

By: Fabio Bergamin From: medicalxpress.com T cells become active in the body only when they recognise a peptide located on one of the immune system’s sentinel cells. The ETH scientists repurposed sentinel cells in such a way that they indicate which peptides the T cells recognise. Medicine has great hopes for personalised cancer immunotherapy. The idea is to have a …